Introduction
Apoptosis is an essential cellular function for normal development and for the maintenance of tissue homeostasis (Wang, 2001; Baehrecke, 2002) . The process of apoptosis is driven by a family of cysteine proteases that are called caspases. Multiple apoptotic signals converge on the mitochondria, which subsequently undergo permeabilization of the outer membrane, resulting in the release of apoptogenic molecules (such as cytochrome c) that activate various caspases (Wang, 2001) . Mitochondrial membrane permeabilization is regulated by the Bcl-2 family of proteins. This protein family comprises both anti-apoptotic members (such as Bcl-2 and Bcl-x L ) and pro-apoptotic members (such as multidomain Bax, Bak and single-domain BH3-only proteins) (Tsujimoto, 2003; Green and Kroemer, 2004) .
It was recently shown that Bax and Bak act as a crucial mitochondrial gateway in inducing apoptosis, as shown by studies of cells lacking both proteins (Wei et al., 2001; Zong et al., 2001) . In healthy cells, Bax normally exists in the cytoplasm as a monomer, can be captured by certain molecules, including 14-3-3 proteins, and is released in response to pro-apoptotic stimuli (Nomura et al., 2003) . The stimulation of apoptosis triggers activation of Bax, which undergoes translocation and integration into the mitochondrial membrane (Wolter et al., 1997; Nechushtan et al., 1999) along with oligomerization and conformational changes (Nechushtan et al., 1999; Antonsson et al., 2000; Eskes et al., 2000) , thus inducing outer-membrane permeabilization. However, the precise mechanisms underlying the activation of Bax are still poorly understood.
The voltage-dependent anion channels (VDACs) are a family of proteins that are abundant in the outer mitochondrial membrane, where they act as the pathway for movement of various substances in and out of the mitochondria (Blachly-Dyson and Forte, 2001; ShoshanBarmatz et al., 2006) . In mammals, three VDAC isoforms (VDAC1, VDAC2 and VDAC3) have been identified, and these are variably expressed in all tissues (Sampson et al., 1996 (Sampson et al., , 2001 . Biochemical studies have revealed that all the three isoforms have similar channel-forming activity, and each can compensate for deficiency of the others (Sampson et al., 1997; Anflous et al., 2001) . However, genetic studies have shown that VDAC2 knockout mice are embryonic lethal, whereas both VDAC1 and VDAC3 knockout mice are viable (Anflous et al., 2001; Sampson et al., 2001; Cheng et al., 2003) , which might suggest that VDAC2 has some different functions from VDAC1 and VDAC3. In addition, activation of Bak has been reported to be regulated by VDAC2, but not VDAC1 (Cheng et al., 2003) .
We have previously shown that VDAC has a crucial role in apoptotic mitochondrial changes by interacting with Bax/Bak and Bcl-x L , based on the findings that (i) these Bcl-2 family members can bind directly to VDAC and modulate its activity (Shimizu et al., 1999) and (ii) inhibition of VDAC activity with neutralizing antibodies suppresses various forms of apoptosis (Shimizu et al., 2001 ), although we did not determine which isoforms were crucial. Even though other groups have also reported evidence for the involvement of VDAC in apoptosis (Madesh and Hajno´czky, 2001; Abu-Hamad et al., 2006 , this concept still remains controversial (Baines et al., 2007) . Here, we extended our studies and showed that VDAC2 has an important role in the activation process of Bax and thus in promoting apoptosis.
Results
We have previously reported that the VDAC, which is a mitochondrial outer-membrane channel protein, has a crucial role in inducing apoptosis through interaction with multidomain Bcl-2 family members (Shimizu et al., 1999 (Shimizu et al., , 2001 ). However, our previous studies lacked any genetic evidence. Therefore, we aimed to investigate the role of VDACs in apoptosis by using VDAC-deficient mouse embryonic fibroblasts (MEFs). As VDAC2 is implicated in apoptosis regulation through binding/ inhibiting Bak (Cheng et al., 2003) , in this study we focused on VDAC2. As mitochondria-mediated apoptosis is dependent on Bax and Bak (Wei et al., 2001; Zong et al., 2001) , we assessed the role of VDAC2 in the activation of Bax and Bak separately by silencing Bax or Bak. Bax and Bak were almost completely suppressed by the relevant siRNAs ( Figure 1a) . These cells were then treated with tunicamycin and apoptosis was assessed by staining with propidium iodide, a dye for nucleic acids that does not cross intact membrane. When Bax was suppressed or when a control siRNA was used, VDAC2-deficient MEFs (DVDAC2 cells) showed a greater sensitivity to apoptosis than wild-type MEFs (WT cells) (Figures 1b and c) , consistent with the previous finding (Cheng et al., 2003) . After silencing of Bak, however, DVDAC2 cells showed superior viability compared with control cells (Figure 1d ). Consistently, DVDAC2 cells were more resistant to etoposide-and thapsigargin-induced apoptosis than control cells when Bak was silenced (Figures 1g and j) , but DVDAC2 cells were more sensitive to apoptosis when Bax was silenced or when neither Bax nor Bak were silenced (Figures 1e, f, h and i). Similar results were also obtained when apoptosis was assessed by annexin V or the CellTiterBlue assay (Supplementary Figures S1, S2 ). These findings indicated that it was difficult for Bax to transmit apoptotic signals to the mitochondria in the absence of VDAC2 in Bak-knockdown cells, suggesting that VDAC2 has a crucial role in Bax-mediated apoptosis. It is noted that when compared with control cells, death was slightly reduced in Bak-silenced cells, (Figures 1b and d) , and similar results were also observed with WT and Bak-knockout MEFs (DBak cells) (see Figure 5 ). Although the reason for this remains unclear, it was not due to a nonspecific action of siRNA, because Bax siRNA and Bak siRNA did not alter the sensitivity of Bax-knockout MEFs (DBax cells) and DBak cells to apoptosis, respectively (Supplementary Figure S3 ).
To confirm that VDAC2 was involved in Baxmediated apoptosis, DVDAC2 cells were infected with a retrovirus expressing murine VDAC2 (pBabemVDAC2-IRES-GFP) or GFP (control vector), and several stable clones were selected. VDAC2 was expressed in VDAC2-transfected DVDAC2 cells (designated as mV2#25 and #26), but not in control DVDAC2 cells (designated as DV2#21 and #22) (Figure 2a ). These cells were subjected to silencing of Bax and Bak (Supplementary Figure S4 ) and then treated with tunicamycin. As shown in Figures 2b and c, introduction of mVDAC2 did not have significant influence on tunicamycin-induced apoptosis in Bax-and controlsilenced cells. In contrast, expression of mVDAC2 restored the ability of DVDAC2 cells to undergo apoptosis in response to tunicamycin, as assessed on the basis of propidium iodide staining (Figure 2d (Figures 3d and e) . In contrast, expression of mVDAC2 did not restore the ability of Bak-silenced VDAC2-deficient cells to undergo apoptosis after stimulation with etoposide (Figure 3h ), although, as expected, expression of mVDAC2 inhibited etoposideinduced apoptosis in Bax-and control-silenced cells (Figures 3f and g ). We do not know the reason why mVDAC2 failed to restore susceptibility of DVDAC2 cells to etoposide-induced apoptosis, but it is conceivable that various apoptotic stimuli show differences in their dependence on Bax or Bak, or that retroviral transduction of mVDAC using a single species of Vdac2 cDNA failed to completely restore the physiological level of VDAC2 activity, resulting in the inability of mVDAC2-transduced DVDAC2 cells to undergo apoptosis after stimulation with etoposide.
To confirm the role of VDAC2 in Bax-dependent apoptosis, Bax was overexpressed in DV2#21 and mV2#25 cells; its expression was almost equivalent in both cells (Figure 4b ). As shown in Figure 4a , mV2#25 cells were efficiently killed by overexpression of Bax, whereas DV2#21 cells were more resistant to Bax overexpression-induced apoptosis regardless of Baksilencing. These results confirm that VDAC2 is crucial for Bax-induced apoptosis.
To further confirm that VDAC2 is necessary for Baxdependent apoptosis, VDAC2 was silenced in DBak, DBax and WT cells, after which these cells were treated with tunicamycin, etoposide, thapsigargin or paclitaxel. VDAC2 expression was sufficiently and specifically suppressed by the siRNA (Figure 5a Requirement of VDAC2 for pro-apoptotic activity of Bax H Yamagata et al on apoptosis sensitivity in other cell line, we examined with Neuro2A derived from mouse neuroblastoma.
As shown in Supplementary Figure S7 , silencing of VDAC2 inhibited apoptosis in Bak-silenced cells. These results indicate that VDAC2 is crucial for Bax-mediated apoptosis in the absence of Bak. Bax is localized to the cytoplasm in healthy cells, and its activation by pro-apoptotic stimuli is associated with translocation/integration into the outer mitochondrial membrane, conformational changes and oligomerization that lead to the release of apoptogenic factors, including cytochrome c (Wolter et al., 1997; Nechushtan et al., 1999; Antonsson et al., 2000; Eskes et al., 2000) . To investigate the role of VDAC2 in the activation of Bax, the active form of Bax was first immunoprecipitated with a specific antibody targeting active Bax and was quantitated by western blotting using another antiBax antibody (which reacted with both active and DV2#21 and mV2#25 cells were silenced with siRNAs for Bak or the non-targeting control, and were treated with 2 mg/ml of tunicamycin (TM) for the indicated periods. Then, cell lysates were subjected to immunoblot analysis to detect active caspase-3 and GAPDH. (f) Inhibition of tunicamycin-induced cytochrome c release in Bak-silenced DVDAC2 cells. DV2#21 and mV2#25 cells were silenced with siRNAs for Bak or the non-targeting control, and were treated with 2 mg/ml of tunicamycin for 24 h. Then the cytosolic fraction was collected from digitonin-permeabilized cells and subjected to immunoblot analysis for cytochrome c and GAPDH.
Requirement of VDAC2 for pro-apoptotic activity of Bax H Yamagata et al inactive Bax). As shown in Figure 6a , active Bax was readily detected in tunicamycin-treated Bak-silenced mV2 cells, but very little was found in Bak-silenced DV2 cells, indicating that VDAC2 is required for Bax activation in Bak-silenced cells. Note that when the control siRNA was employed, a considerable amount of active Bax was even detected in DV2 cells. This might have resulted from a VDAC2-independent mechanism of Bax activation in the presence of Bak or may have been a consequence of cell death (see the Discussion). Consistently, VDAC2-dependent activation of Bax in Bak-silenced cells was confirmed by oligomerization ( Figure 6b ). The extent of Bax activation corresponded well with the extent of apoptosis (Figures 2b and d) . Finally, we examined the translocation/integration of Bax into the mitochondrial membrane. We recovered the mitochondrial membrane fraction using an alkaline solution, which was designed to remove any Bax that was only attached to the mitochondrial membrane and not integrated. As shown in Figure 6c , mitochondrial Bax was almost completely absent in healthy cells. After exposure to tunicamycin, however, a significant amount of Bax underwent integration into the mitochondrial membrane in Bak-silencing mV2 cells, but not DV2 cells, indicating that VDAC2 is crucial for the translocation and membrane integration of Bax. Importantly, even in the presence of Bak, DV2 cells showed a greatly reduced amount of oligomerized and mitochondrial Bax compared with mV2 cells (Figures 6b and c) . All of these results suggest that VDAC2 is required for activation of Bax. Finally, we examined whether Bax interacts with VDAC2. Experiments of immunoprecipitation of Bax followed by VDAC2 western blot indicated that Bax interacted with VDAC2 in response to apoptotic stimulation, not only in WT cells (Figure 6e , Supplementary Figure S8a ) but also in DBak cells (Supplementary Figure S8b) . We confirmed the Bax-VDAC2 Requirement of VDAC2 for pro-apoptotic activity of Bax H Yamagata et al interaction by immunoprecipitation of Flag-tagged VDAC2 followed by Bax western blot (Supplementary Figure S8c) . These results suggest that VDAC2 may contribute to pro-apoptotic activity of Bax through direct binding.
Discussion
We have previously shown that Bax/Bak and Bcl-x L bind to VDAC and modulate its activity (Shimizu et al., 1999) . Mutational studies have suggested that the ability of Bax and Bcl-x L to regulate apoptosis parallels their ability to influence VDAC. In vivo microinjection of two different anti-VDAC antibodies, which inhibit VDAC activity in liposomes, has been shown to suppress some forms of apoptosis, including Bax-mediated apoptosis (Shimizu et al., 2001) . These findings led us to propose that VDAC is involved in Bax-induced permeabilization of the outer mitochondrial membrane during apoptosis. On the basis of our findings that a combination of Bax and VDAC created large non-selective channels and enhanced cytochrome c transport, we proposed that Bax and the VDAC might co-operate to trigger the formation of a protein-conducting channel that contributes to the release of cytochrome c from the mitochondria. This study provides additional evidence for a crucial role of VDAC2 in Bax-mediated apoptosis and Bax activation. Apoptosis-associated translocation/integration of Bax into the mitochondria has been investigated, providing some of the following fragmented pieces of information: (i) in healthy cells Bax exists as a monomer in the cytoplasm and can be sequestered by some proteins including cytoplasmic protein 14-3-3, from which it dissociates in response to apoptotic stimuli (Wolter et al., 1997; Nomura et al., 2003) and (ii) during apoptosis, Bax undergoes various conformational changes, including exposure of the C-terminal region that is essential for its translocation to the mitochondria (Nechushtan et al., 1999; Antonsson et al., 2000; Eskes et al., 2000) . Although such information is useful with respect to understanding the process of Bax activation, an important issue that remains unclear is how Bax preferentially targets the mitochondria during apoptosis. A possible explanation would be the existence of receptors for Bax on the outer mitochondrial membrane and some candidates have been suggested, including cardiolipin (Kuwana et al., 2002) (an acidic phospholipid that is abundant in the inner membrane) and the Tom complex (Bellot et al., 2007; Ott et al., 2007) . VDAC2 might act as an important part of the receptor involved in the translocation of Bax and its integration into the mitochondrial membrane during apoptosis.
Outer mitochondrial membrane proteins are categorized into four groups based on their membrane topology, including proteins with a transmembrane segment localized at the amino-terminus (such as Tom20 and Tom70) and tail-anchored proteins with a single transmembrane segment localized at the carboxyterminus (Rapaport, 2003) . Some members of the Bcl-2 family, including Bak and Bcl-2, belong to the latter group. A recent report has indicated that the integration of these proteins into the mitochondrial membrane does not require the TOM complex, a central protein import system for general mitochondrial precursor proteins, and instead requires VDAC2 (Setoguchi et al., 2006) . These proteins are considered to undergo integration into the mitochondria through the interaction of their C-terminus with VDAC2. Although this has only been shown for proteins that are constitutively localized to the mitochondria, the same might also be true for the apoptotic translocation/integration of Bax, that is, the C-terminal region of Bax is exposed after activation of this protein by pro-apoptotic stimuli, and its integration into the mitochondria occurs through interaction with VDAC2. It is noted that our current findings do not exclude the possibility that VDAC2 may also contribute to the process of mitochondrial membrane permeabilization activated by Bax.
Our current findings show a crucial role of VDAC2 in the process of Bax activation in the absence of Bak. Our data also indicate that when Bak was functional, an alternative VDAC2-independent mechanism of Bax Requirement of VDAC2 for pro-apoptotic activity of Bax H Yamagata et al activation might exist, because activation of Bax (assessed by conformational changes and oligomerization) still occurred in the absence of VDAC2, although much less than in the presence of VDAC2 (Figure 6 ). This observation could represent a consequence of cell death or it could be a process that contributes to apoptotic death. In the latter case, it might be possible that Bak directly recruits and activates Bax or that Bak influences certain mitochondrial molecules to promote the activation of Bax. It has been reported that the Requirement of VDAC2 for pro-apoptotic activity of Bax H Yamagata et al deficiency of both caspases 3 and 7 delays Bax activation (Lakhani et al., 2006) , and that Bax activation depends on caspase 3 activation, which occurs downstream of Bak activation (Neise et al., 2008) . However, our results exclude a role of caspases on Bax activation, because all experiments for Bax activation were performed in the presence of zVAD, a pan-caspase inhibitor. Further studies are necessary to understand the entire process of Bax activation.
Materials and methods

Antibodies and chemicals
The following antibodies were used (numbers in parenthesis indicate the dilutions used for western analysis). Anti-cleavedcaspase-3 (1:1000) and anti-GAPDH (1:1000) monoclonal antibodies were purchased from R&D Systems Inc. Cell culture and transfection Bax KO, Bak KO and wild-type MEFs were harvested from E14.5 mouse embryos, and immortalized with SV40 T antigen. VDAC2 KO and control MEFs were previously described (Cheng et al., 2003) . Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 10 mM HEPES/Na þ (pH 7.4), 0.05 mM 2-mercaptoethanol, 100 U/ml penicillin, 100 mg/ml streptomycin and 10% fetal bovine serum.
The pUC-CAGGS expression vector that contained DNA encoding human Bax has been described elsewhere (Nomura et al., 2003) . Cells (5 Â 10 5 ) were transfected with plasmid DNA using the Amaxa electroporation system according to the supplier's protocol (kit V, program U-20, Lonza, Cologne, Germany). The transfection efficiency was more than 75%, as assessed by co-transfection of DNA for green fluorescence protein (GFP) expression. Murine Vdac2 was cloned into a retroviral expression vector (pBabe-IRES-GFP). Infection of Plat-E cells, which were kindly provided by Dr Kitamura, with the vector was done according to the previous report (Morita et al., 2000) , and several stable clones were collected from among the GFP-positive cells.
All of the siRNAs, which were SMARTpool, were purchased from Dharmacon Research. Cells (1 Â 10 6 ) were transfected twice at an interval of 48 h with 10 mg of siRNA using the Amaxa electroporation system. At 24 h after the second transfection with siRNA, cells were used for the experiments.
Cell viability assay Cells (1 Â 10 5 per well) were seeded into 12-well dishes. After 24 h, the cells were treated with 2 mg/ml of tunicamycin, 5 mM thapsigargin, 20 mM etoposide or 3 mM paclitaxel in the presence or absence of 100 mM zVAD-fmk. Then the cells were harvested and stained for 5 min at room temperature with 1 mM propidium iodide or FITC-conjugated Annexin V, followed by flow cytometric analysis (FACS Caliber; Becton-Dickinson, Franklin Lakes, NJ, USA). Statistical significance was evaluated by means of two-tailed Student's t-test.
Assays of cytochrome c release and Bax activation
For the detection of cytochrome c release, the cytosolic fraction was collected from cells after incubation with 0.1 mg/ ml digitonin for 20 min on ice in isotonic buffer (20 mM HEPES/K þ (pH 7.4), 10 mM KCl, 1.5 mM MgCl 2 , 250 mM sucrose and 1 mM EDTA-2Na). After centrifugation at 8000 r.p.m. ( Â 4800 g avg) for 5 min, aliquots of the supernatant (the cytosolic fraction) were analysed by western blotting with an anti-cytochrome c antibody.
To detect the translocation of Bax to the mitochondrial membrane, mitochondria isolation was performed as follows: Cells (1 Â 10 6 ) were seeded into 10-cm dish and incubated for 24 h. After treatment with 2 mg/ml of tunicamycin and 100 mM zVAD-fmk for 24 h, cells were collected in 500 ml ice-cold isotonic buffer. Cells were homogenized 200 times with tight glass potter homogenizer. After separation of nuclei and unbroken cells by centrifugation at 3300 r.p.m. ( Â 800 g avg) for 10 min twice, the supernatant was centrifuged at 10 000 r.p.m. ( Â 7000 g avg) . The pellet was treated with 100 mM Na 2 CO 3 (pH 11.5) for 20 min on ice. After centrifugation at 15 000 r.p.m. ( Â 15 000 g avg) for 10 min, the pellet was washed twice with PBS, and then were lysed in RIPA buffer (50 mm Tris-HCl (pH 8.0), 0.1% SDS, 1% NP40, 0.5% deoxycholate (sodium salt) and 150 mM NaCl), and boiled with sample buffer for western blotting. Whole cells were also lysed in RIPA buffer and boiled with sample buffer for western blotting (total cell lysate).
The oligomerization of Bax was analysed as follows: After treatment with 2 mg/ml of tunicamycin in the presence of 100 mM zVAD-fmk, cells were harvested and lysed with HNC buffer (25 mM HEPES/Na þ (pH 7.5), 300 mM NaCl, 2% CHAPS and a protease inhibitor cocktail). Then an aliquot of cell lysate (50 mg of protein) was incubated in the presence of 5 mM BMH and 5 mM BS 3 for 30 min at room temperature. For quenching of cross-linkers, 100 mM Tris-HCl (pH 7.5) was added and incubated for 15 min. Finally, Bax oligomers were detected by western blotting.
Immunoprecipitation Cells were treated with 2 mg/ml of tunicamycin or 20 mM etoposide in the presence of 100 mM zVAD-fmk for 24 h. Then cells were harvested, and lysed with HNC buffer. For coimmunoprecipitation of Bax with VDAC2, 500 ml of cell lysates (1.5 mg of protein) were incubated with 10 mg of an anti-Bax polyclonal antibody (N20) or normal rabbit IgG overnight at 4 1C. Each sample was added with 30 ml of protein A beads, and incubated for 3 h. The beads were collected by centrifugation at 3000 r.p.m. ( Â 670 g avg) for 5 min, and the supernatant was discarded. After washing thrice with HNC buffer, the beads were incubated with 30 ml of N20 motif peptide (1 mg/ml) overnight at 4 1C. Protein A beads were centrifuged at 3000 r.p.m. for 5 min, the supernatant was collected and boiled with sample buffer for western blotting. For detection of active Bax, the cell lysates (100 mg of protein) were incubated with 1 mg of an anti-Bax monoclonal antibody (6A7) or normal mouse IgG overnight at 4 1C, followed by incubation with protein A beads for 3 h. The beads were collected by centrifugation at 3000 r.p.m. for 5 min, and the supernatant was discarded. After washing thrice with HNC buffer, the beads were boiled in sample buffer for western blotting.
